I think the potential market for this drug has been greatly overstated. It's a specialty drug, and the market cap has gotten way ahead of itself. Even the best sales projections have a hard time supporting a share price in the $3.20 - $3.60 range. We're going lower.
price target 3.50
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
